Bouygues Energies & Services has been chosen by Valneva to design and build a new Covid-19 vaccine manufacturing facility in Livingston, Scotland
As the main design and build partner, Bouygues Energies & Services will be responsible for the industrial park development.
The master planning of the industrial park began in July 2020, and the production of Covid-19 vaccines will commence in the first half of 2021.
The Covid-19 vaccine manufacturing facility is formed of:
- A new Multi Vaccine Facility (MVF), adjacent to the existing vaccine facility, which will be designed to EU GMP Grade A to D cleanroom standards. The facility will house two manufacturing streams and QC testing laboratories uninterruptedly working to produce Valneva’s inactivated whole-virus Covid-19 vaccine.
- A new warehouse facility that will consist of temperature-controlled storage areas along with goods in and off-loading bays.
- An energy centre that will shelter all essential plant services to serve the main manufacturing facility and associated labs.
- Shared hub facilities that will comprise the main site entrance, offices, employee’s welfare areas as well as the staff car park and the access road for the delivery.
‘Contributing to the global need for solutions’
Steven Weir, CEO of Bouygues Energies & Services, said: “We have an excellent track record working with Valneva and are extremely proud to continue with them on this landmark project.
“We hope that in doing so we can play our small part in the production of this very important vaccine.”
David Lawrence, acting CFO of Valneva, added: “Valneva is proud to be contributing to the global need for solutions to address the Covid-19 disease.
“Our partnership with the UK Government will ensure that our Livingston facility is well prepared to deliver a Covid-19 vaccine during 2021 and beyond.
“Bouygues Energies & Services is a tried and tested partner, we’re working closely with them to ensure that the project is delivered as quickly as possible.”
The facility will ensure readiness for future vaccine development and manufacturing.